

## Innovative, Integrated Translational Research

Since its founding in 2006, CBSET has partnered with more than 400 MedTech and BioTech companies, including start-ups and industry-leading corporations, enabling them to initiate clinical studies and gain subsequent US and OUS market approvals for their novel therapeutic, imaging, and diagnostic technologies.

- **CBSET is a leading Boston-area provider of translational research and product development services for the medical device, pharmaceutical, diagnostic, and biomedical research industries.** CBSET's mission is to help medical device and biotechnology companies develop unique tools and new methods to promote early diagnosis of, and develop innovative treatments for complex diseases.
- **CBSET specializes in the development and application of novel, minimally invasive and surgical techniques in the fields of cardiology, electrophysiology, wound healing, regenerative medicine, endoscopy/laparoscopy, orthopedics, drug and device safety, drug and device delivery, and diagnostic imaging.**
- **CBSET provides GLP (Good Laboratory Practice) and non-GLP a broad range of GLP and non-GLP research services to the medical device, pharmaceutical, and biotech industries, ranging from early product evaluation, through lead optimization and preclinical safety, to physician assessment and training.** CBSET is recognized globally for shortening product lifecycles and time-to-market for novel innovations.
- **CBSET's GLP-compliant, AAALAC-accredited facilities include a 40,000 sq ft state-of-the-art facility in Lexington, and a newly refurbished 22,000 sq ft facility in Grafton, featuring vivaria, catheterization/imaging labs, surgical suites, and dedicated labs for necropsy, histopathology, SEM, and biomechanics.** CBSET offers the latest equipment for fluoroscopy, echocardiography (TEE/TTE), electrophysiology, IVUS, optical coherence tomography (OCT), endoscopy/laparoscopy, surgical video recording, histology, microradiography, and SEM (Scanning Electron Microscopy).
- **CBSET's professional staff includes PhDs, DVMs and recognized experts in device and drug safety, surgery, imaging, specialized histopathology and pathology, veterinary medicine, pharmacology, lead optimization, pharmacokinetics and drug metabolism, and regulatory consulting.** These individuals provide the basis for successful scientific collaborations, rapid concept advancements, unparalleled consulting services, and expert dissemination of information and findings to regulatory and scientific bodies.

**CBSET has been the preclinical partner of choice for more than 400 companies.**

Since its founding, CBSET has become the leader in preclinical biomedical research in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women's health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, combination medical devices, and drug-eluting products.



Peter Markham, CEO

*Our mission is to elevate scientific and medical innovation through creative collaborations with our sponsors and partners that forge new frontiers for improving lives.*

### MANAGEMENT TEAM

**Elazer Edelman, MD, PhD**  
Co-founder & Chairman of the Board;  
Director, Harvard-MIT Biomedical Eng. Center

**Peter M. Markham, MS**  
Co-Founder, President, CEO

**Haim Danenberg, MD**  
Chief Scientific Adviser

**Michael C. John, MPH**  
Regulatory and Innovation Officer (CRIO)

**John Keating, DVM, DACVP**  
VP, Pathology

**Misty J. Williams-Fritze, DVM, MS, DACLAM**  
VP, Veterinary Services

**Taimi Caron**  
VP, Regulatory Compliance

**Shannon Tierney**  
VP, Medical Writing and HR

**Michael Naimark, MS**  
Director, Business Development

**Rami Tzafiriri, PhD**  
Director, Research and Innovation

### What Sponsors say about CBSET...

*"We chose to partner with CBSET because they can provide expert research support for all phases of biomedical discovery and development research."*

-Ray Cohen, Vessix Vascular

*"As a European company, we were very impressed with CBSET's expertise and willingness to work as a team to satisfy the requirements of GLP safety and efficacy studies from start to finish."*

-Barry Russell, neoSurgical